RepliCel Life Sciences Enterprise value
What is the Enterprise value of RepliCel Life Sciences?
The Enterprise value of RepliCel Life Sciences, Inc. is $2.79M
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on TSXV compared to RepliCel Life Sciences
What does RepliCel Life Sciences do?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Companies with enterprise value similar to RepliCel Life Sciences
- 21 St Century Manag has Enterprise value of $2.78M
- New Tech Minerals has Enterprise value of $2.78M
- G Medical Innovations has Enterprise value of $2.78M
- Kollakorn has Enterprise value of $2.78M
- MinKap Resources has Enterprise value of $2.78M
- Home Bistro has Enterprise value of $2.78M
- RepliCel Life Sciences has Enterprise value of $2.79M
- KORE Mining has Enterprise value of $2.79M
- Emu NL has Enterprise value of $2.79M
- Prospex Oil And Gas Plc has Enterprise value of $2.80M
- Darshan Orna has Enterprise value of $2.80M
- Nickel Rock Resources has Enterprise value of $2.80M
- Delta Drone SA has Enterprise value of $2.80M